Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VERVE-201 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Cohort 1: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-201. |
| Cohort 2: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-201. |
| Cohort 3: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-201. |
| Cohort 4: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-201. |
| Cohort 5: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-201. |
| Cohort 6: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-201. |
| Name | Type | Description |
|---|---|---|
| VERVE-201 | DRUG | Intravenous (IV) infusion |
Inclusion Criteria: * Refractory hypercholesterolemia * Refractory hypertriglyceridemia Exclusion Criteria: * Active or history of chronic liver disease * Current treatment with monoclonal antibody targeting ANGPTL3 or prior treatment within specified timeframe * Clinically significant or abnorma...
Top 12 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Arrowhead Pharmaceuticals, Inc. | ARWR | 7 | PHASE3 | zodasiran, Plozasiran |
| Novartis AG Sponsored ADR | NVS | 11 | PHASE3 | Inclisiran, Pelacarsen, DII235 |
| Merck & Co., Inc. | MRK | 3 | PHASE3 | Enlicitide |
| AstraZeneca PLC | AZN | 1 | PHASE3 | AZD0780 |
| Ionis Pharmaceuticals, Inc. | IONS | 1 | PHASE3 | Olezarsen |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE2 | Alirocumab |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Solbinsiran |
| MediciNova, Inc. | MNOV | 1 | PHASE2 | MN-001 |
| NewAmsterdam Pharma Company N.V. | NAMS | 1 | PHASE1 | Obicetrapib |
| Verve Therapeutics, Inc. | VERV | 3 | PHASE1 | VERVE-102, VERVE-201 |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX310 |
| Esperion Therapeutics, Inc. | ESPR | 1 | - | Bempedoic acid+ Ezetimibe |
VERVE-201 is an investigational small molecule being developed for the treatment of hypercholesterolemia, a condition characterized by high cholesterol levels. It is also being studied in patients with refractory hyperlipidemia, which includes both hypercholesterolemia and hypertriglyceridemia. The drug is currently in Phase 1 clinical development.
VERVE-201 targets ANGPTL3, a protein that regulates lipid metabolism. By targeting ANGPTL3, the drug aims to address elevated cholesterol and triglyceride levels. This mechanism is being evaluated in a Phase 1b study for patients with refractory hyperlipidemia.
VERVE-201 is being developed by Verve Therapeutics, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol VERV. The company is conducting a Phase 1b clinical trial of VERVE-201 in patients with refractory hyperlipidemia.
VERVE-201 is in Phase 1 clinical development. The ongoing trial is a Phase 1b study designed to evaluate the drug in patients with refractory hyperlipidemia. The study is currently recruiting participants and has not yet been completed.
VERVE-201 is being studied in a Phase 1b clinical trial registered as NCT06451770. This trial is recruiting patients with refractory hyperlipidemia, including those with hypercholesterolemia and hypertriglyceridemia. The study is enrolling 36 participants across multiple countries, including the United States, Australia, Canada, the Netherlands, South Africa, and the United Kingdom.
VERVE-201 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The ongoing Phase 1b trial is recruiting patients to evaluate the drug's safety and efficacy in treating refractory hyperlipidemia, but it has not yet received regulatory approval.